ICD-11 code : 1D60.1;
Preferred Label : Marburg disease;
ICD-11 definition : A severe disease with high case fatality caused by infection with virus of the Orthomarburgvirus
genus. Marburg disease is typically characterised by acute onset of fever with non-specific
symptoms/signs (e.g., abdominal pain, anorexia, fatigue, malaise, myalgia, sore throat)
usually followed several days later by nausea, vomiting, diarrhoea, and occasionally
a variable rash. Severe illness may include haemorrhagic manifestations (e.g., bleeding
from puncture sites, ecchymoses, petechiae, visceral effusions), encephalopathy, shock/hypotension,
multi-organ failure. Common laboratory findings include thrombocytopenia, elevated
transaminase concentrations, electrolyte abnormalities, and signs of renal dysfunction.
Individuals who recover may experience prolonged sequelae (e.g., arthralgia, neurocognitive
dysfunction, uveitis). Viral persistence has been documented in immune-privileged
compartments (e.g., CNS, eyes, testes) in some people who recovered. Person-to-person
transmission occurs by direct contact with blood, other bodily fluids, organs, or
contaminated surfaces and materials with risk beginning at the onset of clinical signs
and increasing with disease severity. Family members, healthcare providers and other
people providing care to patients,and people with direct contact with the deceased
are at particular risk. The incubation period typically is 7–11 days (range 2–21
days).;
ICD-11 synonym : green monkey disease; vervet monkey disease; MARD - [Marburg disease];
ICD-11 acronym : MARD;
ICD-11 "other" category code : 1D60.1Y;
ICD-11 "unspecified" category code : 1D60.1Z;
Origin ID : 696598707;
UMLS CUI : C0024788;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
ICD-10 Mapping
Semantic type(s)
UMLS correspondences (same concept)
A severe disease with high case fatality caused by infection with virus of the Orthomarburgvirus
genus. Marburg disease is typically characterised by acute onset of fever with non-specific
symptoms/signs (e.g., abdominal pain, anorexia, fatigue, malaise, myalgia, sore throat)
usually followed several days later by nausea, vomiting, diarrhoea, and occasionally
a variable rash. Severe illness may include haemorrhagic manifestations (e.g., bleeding
from puncture sites, ecchymoses, petechiae, visceral effusions), encephalopathy, shock/hypotension,
multi-organ failure. Common laboratory findings include thrombocytopenia, elevated
transaminase concentrations, electrolyte abnormalities, and signs of renal dysfunction.
Individuals who recover may experience prolonged sequelae (e.g., arthralgia, neurocognitive
dysfunction, uveitis). Viral persistence has been documented in immune-privileged
compartments (e.g., CNS, eyes, testes) in some people who recovered. Person-to-person
transmission occurs by direct contact with blood, other bodily fluids, organs, or
contaminated surfaces and materials with risk beginning at the onset of clinical signs
and increasing with disease severity. Family members, healthcare providers and other
people providing care to patients,and people with direct contact with the deceased
are at particular risk. The incubation period typically is 7–11 days (range 2–21
days).